Form MD-13 is a specific licence for manufacturing medical devices in limited quantities for clinical investigation, testing, evaluation, demonstration, or training. It serves a controlled regulatory purpose and should not be treated as permission for unrestricted commercial manufacture or sale. The regulatory process begins with an application in Form MD-12, while Form MD-13 represents the licence granted by the competent central licensing authority after applicable requirements are satisfied.
Device developers and manufacturers should therefore identify the proposed device, manufacturing premises, intended purpose, required quantity, personnel, facilities and supporting technical information before seeking this authorisation.
What Is Form MD-13?
Form MD-13 is the licence granted for manufacturing medical devices for specified limited purposes. These purposes relate primarily to development, investigation, testing and controlled non-commercial use rather than routine market supply.
The licence may authorise manufacture for:
- Clinical investigation
- Test
- Evaluation
- Demonstration
- Training
Its regulatory significance lies in allowing a manufacturer or developer to produce devices that are genuinely needed for one or more of these purposes without treating such production as ordinary commercial manufacturing.
The authorised purpose remains important throughout the licence period. A business cannot properly treat units produced under this route as unrestricted commercial inventory simply because they have been manufactured at an authorised facility.
Likewise, holding this licence does not independently provide every other approval that a project may require. Clinical investigation permission, import authorisation, commercial manufacturing permission and other regulatory processes remain distinct where applicable.
MD-12 and MD-13: The Essential Distinction
A fundamental regulatory distinction separates these two forms: MD-12 is the application, whereas MD-13 is the resulting licence.
A manufacturer seeking permission to produce devices for the specified limited purposes applies in Form MD-12. The relevant central licensing authority then considers the application, supporting information, and applicable requirements. Where the authority is satisfied, it may grant the licence in Form MD-13.
Consequently, describing MD-13 as the application creates an important terminology error. The distinction also affects documentation, regulatory correspondence and internal records.
Businesses should therefore use the forms consistently:
- MD-12: application seeking the licence
- MD-13: licence authorising specified manufacture
Accurate terminology helps regulatory, quality and manufacturing teams distinguish an application under review from an authorisation that has actually been granted.
Why This Licence Exists
Medical device development often requires physical units before unrestricted commercial manufacturing begins. Developers may need prototypes or production-stage devices for technical testing, performance assessment, investigation, demonstrations or user training.
A controlled manufacturing route accommodates these legitimate requirements while maintaining regulatory oversight.
For example, a manufacturer may need a defined quantity to complete testing against relevant specifications. Another project may require units for an authorised clinical investigation. A developer could also need devices for structured evaluation before finalising manufacturing decisions.
Demonstration and training can create similar needs. However, the manufacturer should connect the quantity produced with the declared purpose.
Therefore, the licence creates a regulatory boundary between controlled manufacture for specified purposes and manufacture intended for ordinary commercial supply.
MD-13 Is Not Permission for Commercial Sale
The limited purpose of the licence is central to its operation. It should not be interpreted as general permission to manufacture unlimited quantities for sale, marketing or routine commercial distribution.
A manufacturer should produce devices consistently with the purpose and quantity covered by the authorisation. Producing unrestricted inventory under a test-manufacturing route would conflict with the regulatory distinction between development-related production and commercial manufacturing.
Commercial manufacture follows the applicable authorisation route based on factors such as device classification and regulatory circumstances.
Furthermore, demonstration units should not automatically enter commercial channels after being displayed, and training units should not become saleable stock merely because their original use has finished.
Internal controls should consequently separate units manufactured under this licence from normal commercial inventory and preserve traceability of their authorised use.
Who May Need This Authorisation?
The licence can become relevant to different organisations involved in medical device development or controlled pre-commercial activity. However, not every medical device business requires it.
Potential applicants may include:
- Startups developing medical devices
- Established medical device manufacturers
- Research and development units
- Organisations producing devices for testing
- Manufacturers preparing evaluation units
- Developers requiring clinical investigation units
- Businesses manufacturing demonstration devices
- Manufacturers preparing devices for training
An existing manufacturer may require the route when developing an additional device even though it already conducts authorised commercial manufacturing for other products.
Conversely, a business that merely distributes commercially manufactured devices should not assume that this licence applies to its activity.
The correct regulatory route depends on what the organisation intends to manufacture and why it needs those units.
Device Identity and Classification
A strong application starts with precise identification of the medical device. The applicant should ensure that the regulatory description corresponds with the product actually proposed for manufacture.
Relevant information can include:
- Generic device name
- Device type
- Intended purpose
- Applicable device class
- Quantity proposed
- Reason for manufacture
Medical devices may fall within Class A, Class B, Class C or Class D, depending on the applicable classification framework. The applicant should determine the appropriate classification for the specific device rather than selecting a class based on assumption.
Classification matters because it provides regulatory context for the product and may influence other obligations. Nevertheless, an explanation of MD-13 does not require treating classification as a separate licensing exercise.
Consistency is particularly important. Device descriptions used across technical records, applications, test documentation and internal development files should not contradict each other without a documented reason.
Proposed Quantity and Its Justification
Quantity is not merely an administrative figure. The application should justify how many devices the manufacturer proposes to produce and explain how those units will be utilised.
A useful justification connects quantities directly with planned activities. For example, units may be allocated between testing, evaluation, clinical investigation, demonstration or training, depending on the project’s legitimate requirements.
The utilisation breakdown should make the intended use reasonably clear.
No universal quantity can be assumed for every device because development programmes differ substantially. A simple device undergoing limited technical testing may require a different quantity from a product involved in a broader evaluation programme.
Consequently, applicants should calculate quantities from genuine project requirements rather than requesting an arbitrarily large number for operational convenience.
Why Quantity Control Matters
Quantity control reinforces the limited nature of the authorisation. It helps demonstrate that manufacturing relates to a defined regulatory, technical or developmental purpose rather than unrestricted inventory creation.
Internal production records should therefore correspond with the authorised quantity.
Where development requirements materially change, the manufacturer should assess the applicable regulatory position before producing additional units rather than assuming that the original authorisation permits unlimited expansion.
Applying Through Form MD-12
The regulatory journey begins with Form MD-12. The application should clearly communicate what the manufacturer intends to produce, where production will occur, why the devices are required, and how the proposed quantity relates to the declared purpose.
Supporting material may vary according to the device and circumstances. However, the application package should create a coherent picture of the proposed activity.
A practical preparation sequence involves:
- Identifying the device accurately.
- Checking its applicable classification.
- Defining the intended limited purpose.
- Calculating and justifying the proposed quantity.
- Confirming the manufacturing premises.
- Reviewing manufacturing and testing facilities.
- Identifying qualified personnel.
- Preparing process and testing information.
- Checking supporting documentation.
- Reviewing consistency before submission.
This preparation cannot guarantee the grant of the licence because the authority retains responsibility for assessing applicable requirements.
Purpose and Supporting Explanation
The application should clearly state why the manufacturer needs the authorisation. Vague statements such as “development purposes” may provide less regulatory clarity than an explanation linked to actual planned activities.
Depending on the project, the stated purpose may concern clinical investigation, testing, evaluation, demonstration or training.
The supporting explanation should remain consistent with quantity calculations and technical documentation. For instance, if all proposed units are intended for testing, the utilisation information should logically correspond with the planned test programme.
Similarly, an application involving several permitted purposes should explain the proposed allocation appropriately.
Clear purpose statements also support internal compliance after grant because manufacturing, quality and regulatory personnel can identify how authorised units may legitimately be used.
Manufacturing Facilities, Equipment and Personnel
Permission to manufacture limited quantities still requires attention to the environment in which manufacturing and testing will occur. The applicant should demonstrate the availability of facilities, equipment, instruments and personnel appropriate to the proposed activity.
Manufacturing and Testing Facilities
Relevant considerations can include manufacturing areas, utilities, production equipment, measuring instruments, testing facilities and quality controls appropriate to the device.
There is no sensible universal equipment list for every application because an implantable product, diagnostic equipment and a comparatively simple non-active device can involve substantially different manufacturing and testing needs.
Applicants should therefore describe equipment that genuinely supports their proposed process.
An undertaking regarding the availability of required facilities, equipment, instruments and personnel may form part of the supporting documentation.
Qualified Personnel
The application documentation should identify qualified personnel involved in manufacturing and testing. Their roles should correspond with the technical activities they are expected to perform.
Universal qualification requirements should not be assumed without considering the applicable regulatory requirements and device.
Nevertheless, the core principle remains important: a regulated manufacturing activity should rely on personnel capable of performing and controlling the relevant operations.
Changes in personnel during the authorised period should therefore receive appropriate internal quality and regulatory attention.
Manufacturing Process and Testing Information
The application should provide sufficient information about how the proposed device will be manufactured and tested. A brief description of manufacturing and testing processes, supported by an appropriate flowchart, can help present the sequence clearly.
Process information may cover:
- Principal production stages
- Intermediate checks
- Testing stages
- Relevant quality controls
- Final evaluation activities
The level of detail should correspond with the device and proposed manufacturing activity.
Test specifications, protocols, relevant standards and performance criteria may also form part of the technical package where applicable. Applicants should use requirements appropriate to their specific device rather than copying unrelated standards from another product.
Consistency between the process description, equipment list and test documentation matters. For example, a testing protocol should not depend on specialised equipment that the application otherwise fails to identify or make available.
Existing Manufacturing and Research Arrangements
Some applicants may already hold manufacturing authorisation for other medical devices at the proposed premises. Existing permission can be relevant to the regulatory assessment where applicable, but holding a commercial manufacturing licence should not automatically be treated as a substitute for MD-13 when the specific activity requires this route.
Similarly, research and development authorisation or related documentation may be relevant depending on the applicant’s circumstances.
Not every applicant should be assumed to possess identical R&D approvals. The regulatory package should reflect the actual organisational arrangement and applicable requirements.
An established manufacturer and an early-stage development organisation may therefore present different supporting backgrounds while still needing to establish suitable premises, facilities, personnel and controls for the proposed manufacturing activity.
Medical Device Licensing for West Bengal Facilities
A manufacturer considering a medical device licence in West Bengal should distinguish controlled MD-13 manufacturing from routine commercial authorisation and align the device, premises, intended purpose, quantity, personnel and technical records before submitting Form MD-12.
Location within the state does not create a separate state-specific version of MD-13. The licence operates within India’s central medical device regulatory framework.
Therefore, the relevant central licensing authority grants the authorisation.
At the same time, operating a manufacturing facility in West Bengal may involve separate obligations concerning premises, business operations, labour, environmental matters or other locally applicable requirements. MD-13 does not automatically replace those obligations.
This distinction prevents businesses from treating one central medical device authorisation as a universal approval for every aspect of facility operation.
Clinical Investigation, Testing and Evaluation
The permitted purposes require careful distinction because each describes a particular reason for producing controlled quantities.
Clinical Investigation Units
MD-13 may enable lawful manufacture of devices required for clinical investigation. However, the manufacturing licence is not itself permission to conduct that investigation.
Where separate clinical investigation authorisation or regulatory requirements apply, the responsible parties must address them independently.
This distinction matters because manufacturing a device and conducting an investigation with human participants represent separate regulated concepts.
The manufacturer should therefore ensure that units intended for investigation remain traceable to their stated purpose and that their manufacture does not become confused with permission to commence clinical activities.
Testing and Evaluation Units
Testing may involve activities intended to verify performance, assess design, check specifications or generate technical information.
Evaluation can similarly form part of structured development work used to assess device characteristics or suitability. However, applicants should avoid assigning artificial labels merely to bring ordinary commercial production within the limited licensing route.
Testing plans should connect logically with proposed quantities, equipment, protocols and intended outcomes.
Development records should also document relevant results and significant changes arising from evaluation.
Demonstration and Training Units
Demonstration allows a device to be produced for legitimate presentation or demonstration rather than ordinary commercial distribution. The authorised purpose should remain clear in internal records.
Training units can support activities such as:
- User familiarisation
- Technical instruction
- Product-handling training
- Appropriate clinical training
Training use does not convert the licence into commercial manufacturing permission, nor does it independently establish clinical claims for the product.
Manufacturers should maintain appropriate control over where such units go and how they are used.
Where demonstration or training units are returned, retained or otherwise dealt with after their authorised purpose, the manufacturer should follow applicable requirements and internal controls rather than automatically moving them into commercial stock.
MD-13 Versus Import Test Licensing
Domestic manufacture and import for test-related purposes involve different regulatory routes.
MD-13 concerns manufacture of medical devices for specified purposes such as clinical investigation, testing, evaluation, demonstration or training.
In contrast, MD-17 relates to import of medical devices for relevant test, evaluation, clinical investigation, demonstration or training purposes.
This difference turns on the activity being authorised. A manufacturer producing devices domestically should not treat an import-test route as equivalent merely because the eventual purpose is testing.
Similarly, importing devices does not become domestic manufacture simply because evaluation will occur at an Indian facility.
Regulatory teams should therefore identify both the source of the device and its intended use before selecting the appropriate route.
Licence Conditions and Controlled Manufacturing
Once granted, the licence should be used only within its authorised scope. Manufacturing teams need controls that translate regulatory particulars into operational instructions.
Key considerations include:
- Manufacturing only the authorised device
- Respecting the authorised quantity
- Using units for permitted purposes
- Operating from the identified premises
- Maintaining appropriate manufacturing records
- Preserving testing information
- Controlling distribution of test units
- Preventing unauthorised commercial sale
The premises identified in the licence are particularly significant. Moving manufacturing activity elsewhere should not be treated merely as an internal logistical decision because the authorisation identifies the location at which specified devices may be manufactured.
Likewise, the manufactured device should remain consistent with its approved identity, classification, quantity, intended purpose and other relevant particulars.
Records and Traceability After Grant
Record keeping demonstrates how the licence has actually been used. The licence holder must maintain records concerning quantities manufactured, while broader traceability can support effective regulatory and quality control.
Depending on the device and process, practical records may cover:
- Quantity manufactured
- Batch or lot information where relevant
- Manufacturing dates
- Intended use
- Testing allocation
- Investigation allocation where applicable
- Demonstration or training allocation
- Relevant distribution information
- Return or disposal where applicable
Manufacturers should not invent record formats based solely on convenience when specific applicable requirements exist. However, records should permit meaningful reconciliation between authorised quantities, actual production and use.
Testing records are equally valuable because they connect manufactured units with the technical purpose for which production occurred.
Validity and Changes During Development
An MD-13 licence remains in force for three years unless cancelled earlier. Manufacturers should monitor this period and assess applicable requirements before continuing regulated manufacturing beyond the authorised duration.
Development rarely remains static. Design, process or intended-use changes may arise as testing generates new information.
Significant changes involving device design, classification, intended purpose, manufacturing premises, proposed quantity or manufacturing processes may require regulatory assessment depending on their nature and applicable requirements.
Manufacturers should therefore document development-stage changes and assess their effect before implementation.
Process modifications should remain traceable, while changes in testing methods should be reflected in relevant controlled records.
A manufacturing-site change deserves particular attention because the licence identifies authorised premises. Businesses should determine the appropriate regulatory treatment rather than assuming that authorisation follows the equipment automatically.
Regulatory Enquiry and Application Review
The licensing authority may make enquiries considered necessary when assessing the application. This does not mean that every application necessarily follows an identical inspection pathway.
Applicants should instead maintain readiness to substantiate information submitted in Form MD-12.
Before submission, regulatory and quality teams should cross-check:
- Device name and description
- Classification
- Intended purpose
- Proposed quantity
- Quantity utilisation
- Manufacturing premises
- Equipment and instruments
- Qualified personnel
- Manufacturing process
- Testing process and specifications
Questions can arise where the intended purpose is unclear, quantity justification is weak, premises information conflicts across documents, or technical records do not support the stated manufacturing and testing arrangements.
A coherent application reduces such avoidable inconsistencies without guaranteeing a particular regulatory outcome.
Common Misconceptions and Application Mistakes
Several misconceptions can distort the regulatory purpose of this licence. It is not the application form, an import authorisation, unrestricted commercial manufacturing permission, or automatic clinical investigation approval.
Common practical mistakes include:
- Confusing Form MD-12 with Form MD-13
- Applying without defining a clear permitted purpose
- Providing inadequate quantity justification
- Using an incorrect or unsupported device classification
- Submitting incomplete manufacturing-process information
- Omitting relevant testing equipment or instruments
- Providing incomplete personnel information
- Using inconsistent manufacturing-premises details
- Treating the licence as permission for commercial sale
- Failing to maintain quantity records after grant
Another mistake involves assuming that an existing commercial manufacturing permission automatically eliminates every need for a separate controlled manufacturing authorisation. The appropriate route should instead be assessed from the specific device and proposed activity.
Pre-Application Checklist
Before filing Form MD-12, review whether:
- The device has been identified accurately.
- Its applicable class has been checked.
- The intended purpose is clearly defined.
- The proposed quantity has been calculated.
- Quantity utilisation has been justified.
- Manufacturing premises are confirmed.
- Manufacturing equipment is listed.
- Testing instruments are identified.
- Qualified personnel are identified.
- Manufacturing processes are documented.
- Testing processes are documented.
- An appropriate process flowchart is prepared.
- Test specifications and protocols are available.
- Relevant standards are identified where applicable.
- Existing manufacturing permission is reviewed where relevant.
- R&D-related authorisation is reviewed where applicable.
- Supporting documents are consistent.
- Application particulars have been proofread.
This review supports application quality but cannot guarantee licence grant.
Post-Licence Compliance Checklist
After receiving the authorisation, operational controls remain essential. The licence holder should ensure that:
- Only authorised devices are manufactured.
- Production remains within the authorised quantity.
- Units serve only permitted purposes.
- Quantity records remain current.
- Appropriate traceability is maintained.
- Manufacturing records remain controlled.
- Testing records are preserved appropriately.
- Significant changes receive regulatory assessment where necessary.
- Licence validity is monitored.
- Units are not sold commercially under the test licence.
Internal responsibility should be clear among regulatory, quality, manufacturing and testing personnel. Moreover, teams should reconcile actual production against authorised quantities periodically rather than waiting until the end of a development programme.
These controls help preserve the distinction between controlled development manufacture and ordinary commercial production.
Conclusion
MD-13 provides a controlled regulatory route for manufacturing medical devices needed for clinical investigation, testing, evaluation, demonstration or training. Effective compliance starts with correct device identification and classification, a clearly defined purpose, justified quantities, suitable premises, appropriate equipment and qualified personnel. Manufacturing and testing documentation should support the proposed activity, while post-grant records should preserve quantity control and traceability.
Most importantly, manufacturers should keep this limited authorisation separate from commercial manufacturing, import permission and clinical investigation approval, monitor its validity and assess significant development changes against applicable regulatory requirements.
FAQs
1. What is Form MD-13?
Form MD-13 is the licence granted for manufacturing medical devices in limited quantities for specified purposes such as clinical investigation, testing, evaluation, demonstration or training. It authorises controlled manufacturing within its applicable scope and should not be treated as general permission for unrestricted commercial manufacture, marketing or sale.
2. Is MD-13 an application form or a licence?
MD-13 is a licence, not the application used to request that authorisation. A manufacturer seeking permission for the relevant controlled manufacturing activity applies through Form MD-12. After considering the application and applicable requirements, the relevant central licensing authority may grant the manufacturing licence in Form MD-13.
3. What is the difference between MD-12 and MD-13?
Form MD-12 initiates the regulatory request for permission to manufacture medical devices for specified test-related purposes. Form MD-13 represents the licence granted after regulatory assessment. Therefore, one records the applicant’s request, while the other provides the resulting authorisation subject to its scope, particulars and applicable conditions.
4. Can devices manufactured under MD-13 be sold commercially?
The licence should not be treated as permission for routine commercial manufacture or unrestricted sale. Devices produced under it are associated with specified purposes such as testing, evaluation, clinical investigation, demonstration or training. Commercial manufacturing and distribution require the appropriate regulatory authorisation applicable to the particular device and circumstances.
5. Can MD-13 be used for clinical investigation units?
Yes, the licence can cover manufacture of devices required for clinical investigation within its authorised scope. However, permission to manufacture those units does not itself authorise conduct of the clinical investigation. Any separate permissions and requirements applicable to the investigation must therefore be addressed independently by the responsible parties.
6. Must the proposed manufacturing quantity be justified?
Quantity justification is an important application consideration because the authorisation concerns controlled manufacturing for defined purposes. Applicants should explain the proposed quantity and its intended utilisation, connecting the units with testing, investigation, evaluation, demonstration or training requirements. There is no appropriate universal quantity that can simply be assumed for every device.
7. Is MD-13 the same as an import test licence?
No. MD-13 concerns domestic manufacture of medical devices for specified limited purposes. The import route for devices intended for test, evaluation, clinical investigation, demonstration or training uses a different regulatory authorisation. Applicants should therefore distinguish whether devices will be manufactured domestically or brought into India from outside the country.
8. Does an existing commercial manufacturing licence replace MD-13?
Not automatically. An existing commercial manufacturing authorisation may be relevant to the premises and regulatory background, but the correct route depends on the proposed device and activity. A manufacturer should assess whether the particular controlled manufacture requires MD-13 rather than assuming that an existing permission covers every development or test-related activity.
9. What records should an MD-13 licence holder maintain?
The licence holder should maintain required records concerning quantities manufactured. Appropriate supporting traceability can also connect production with testing, clinical investigation, evaluation, demonstration or training use. Depending on the device, manufacturing, batch or lot, testing, distribution, return and disposal information may also support effective regulatory and quality control.
10. Can a West Bengal manufacturer apply under this framework?
Yes. A manufacturer operating from West Bengal can seek the authorisation through India’s applicable national medical device regulatory framework when its proposed activity falls within the relevant scope. The manufacturer’s location does not create a separate state-specific MD-13 regime, although other local or state-level operational requirements may independently apply.
